StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)

Close on Nov 17, 2026Market cap $93.66MP/E –Yield –

Voyager Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Voyager Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$120.57M. For fiscal 2025 it was -$132.47M. The highest annual figure on record is $77.92M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.47M–
FY2024Dec 31, 2024-$15.31M-119.6%
FY2023Dec 31, 2023$77.92M–
FY2022Dec 31, 2022-$12.51M–
FY2021Dec 31, 2021-$53.53M–
FY2020Dec 31, 2020-$96.72M-298.7%
FY2019Dec 31, 2019$48.67M–
FY2018Dec 31, 2018-$15.89M–
FY2017Dec 31, 2017-$61.35M–
FY2016Dec 31, 2016-$42.48M-202.9%
FY2015Dec 31, 2015$41.30M–
FY2014Dec 31, 2014-$11.92M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.84M–
Q1 FY2026Mar 31, 2026-$33.42M–
Q4 FY2025Dec 31, 2025-$30.26M–
Q3 FY2025Sep 30, 2025-$31.05M–
Q2 FY2025Jun 30, 2025-$33.26M–
Q1 FY2025Mar 31, 2025-$37.90M-164.5%
Q4 FY2024Dec 31, 2024-$14.53M–
Q3 FY2024Sep 30, 2024-$27.97M–
Q2 FY2024Jun 30, 2024-$31.58M–
Q1 FY2024Mar 31, 2024$58.77M-52.4%
Q4 FY2023Dec 31, 2023-$23.76M–
Q3 FY2023Sep 30, 2023-$21.05M–
Q2 FY2023Jun 30, 2023-$835.00K–
Q1 FY2023Mar 31, 2023$123.57M+258.9%
Q4 FY2022Dec 31, 2022-$12.24M-209.4%
Q3 FY2022Sep 30, 2022-$16.21M–
Q2 FY2022Jun 30, 2022-$18.49M–
Q1 FY2022Mar 31, 2022$34.43M–
Q4 FY2021Dec 31, 2021$11.20M–
Q3 FY2021Sep 30, 2021-$20.71M–
Q2 FY2021Jun 30, 2021-$22.72M–
Q1 FY2021Mar 31, 2021-$21.29M–
Q4 FY2020Dec 31, 2020-$21.98M–
Q3 FY2020Sep 30, 2020-$24.74M–
Q2 FY2020Jun 30, 2020-$21.20M–
Q1 FY2020Mar 31, 2020-$28.80M-123.0%
Q4 FY2019Dec 31, 2019-$23.36M–
Q3 FY2019Sep 30, 2019-$21.58M–
Q2 FY2019Jun 30, 2019-$31.56M–
Q1 FY2019Mar 31, 2019$125.16M+157.5%
Q4 FY2018Dec 31, 2018-$24.35M–
Q3 FY2018Sep 30, 2018-$17.65M–
Q2 FY2018Jun 30, 2018-$22.50M–
Q1 FY2018Mar 31, 2018$48.61M–
Q4 FY2017Dec 31, 2017-$14.83M–
Q3 FY2017Sep 30, 2017-$15.89M–
Q2 FY2017Jun 30, 2017-$16.34M–
Q1 FY2017Mar 31, 2017-$14.29M–
Q4 FY2016Dec 31, 2016-$13.09M–
Q3 FY2016Sep 30, 2016-$10.19M–

More Voyager Therapeutics figures

See a number that looks wrong?